Context Therapeutics Announces First Patient Dosed In Phase 1 Trial Of Nectin-4 x CD3 Bispecific CT-202 In Urothelial, Colorectal, And Triple-Negative Breast Cancers; Says Initial Phase 1a Data Expected In H2 2027

Loading news article.

Context Therapeutics Announces First Patient Dosed In Phase 1 Trial Of Nectin-4 x CD3 Bispecific CT-202 In Urothelial, Colorectal, And Triple-Negative Breast Cancers; Says Initial Phase 1a Data Expected In H2 2027 | WAPE

Context Therapeutics Announces First Patient Dosed In Phase 1 Trial Of Nectin-4 x CD3 Bispecific CT-202 In Urothelial, Colorectal, And Triple-Negative Breast Cancers; Says Initial Phase 1a Data Expected In H2 2027

Article summary

Related companies

Comments —